CD34 and acute myeloid leukemia: Finally, in contrast to the patients identified based on the clustering analysis of all highly differing proteins (i.e., more than 2-fold and including several differentiation markers; see Figure 2), the patient subsets with adverse prognosis identified in the clustering analysis of iron/ferroptosis markers (Figure 3) did not differ from the other patients with regard to age, morphological AML cell differentiation, AML cell expression of the CD34 stem cell marker, or genetic abnormalities.